Preclinical work validated the ability of anti-TIGIT mAbs to effectively inhibit T-cell proliferation and enhance the anti-tumor immune response, either as a standalone therapy or in conjunction with other immune checkpoint inhibitors [112]. Here, TIGIT is linked to neoplasm.